Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
AssigneeWashington Research Foundation
InventorDavid R. Eyre
Life of this patent
Estimating the term…
Abstract
Methods of determining collagen degradation in vivo, by quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link. Suitable methods include immunometric assays, fluorometric assays, and electrochemical titrations for quantitation. The structure of specific peptides having cross-links and kits for quantitating these peptides in a body fluid are described.
Claims2
A cell line that produces a specific binding partner that binds to first and second peptides consisting essentially of the structure ##STR14## is hydroxylysyl pyridinoline or lysyl pyridinoline, and Gln is glutamine or pyrrolidine carboxylic acid, and wherein the pyridinium ring of the cross-linking amino acid in the first and second peptides is closed and open, respectively, the cell line having the identifying characteristics of ATCC HB 10611.
Dependencies are inferred from the claim text.